Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 placebo-controlled trial of rPhleum SCIT in grass pollen allergic rhinoconjunctivitis
2009-011504-36Phase 3Completed
- Sponsor
- Allergopharma
- Start
- Jul 2009
- Modality
- Subcutaneous Immunotherapy → Allergy Immunotherapy → Therapeutic Vaccines → Vaccines & Immunotherapeutics, Sublingual Immunotherapy → Allergy Immunotherapy → Therapeutic Vaccines → Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in allergic rhinitis (AR), allergic rhinoconjunctivitis (ARC) and grass pollen allergy comparing rPhleum with Placebo (2 arms). Primary endpoint: Change of AUC of medication-adjusted Rhinoconjunctivitis Symptom Score from baseline to season after 2 years. Started Jul 2009; status: completed.
02
Drugs
recombinant timothy grass pollen allergen cocktail
03
Conditions
allergic rhinitis (AR)allergic rhinoconjunctivitis (ARC)grass pollen allergy
Beyond the preview
Go deeper on 2009-011504-36.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-011504-36.